Education
About Us
Working with TipRanks
Follow Us
Andlauer Healthcare Group (TSE:AND)
TSX:AND
RESEARCH TOOLSreports
Top Page
Andlauer Healthcare Group
(TSX:AND)
65Neutral
Andlauer Healthcare Group (AND) vs. S&P 500 (SPY)
Market Cap
$1.56B
Dividend Yield1.12%
Average Volume (3M)33.55K
Price to Earnings (P/E)25.1
Beta (1Y)0.67
Revenue Growth0.39%
EPS Growth1.28%
CountryCA
Employees2,300
SectorHealthcare
Sector Strength78
IndustryTransportation
Share Statistics
EPS (TTM)1.60
Shares Outstanding18,443,497
10 Day Avg. Volume42,245
30 Day Avg. Volume33,551
Financial Highlights & Ratios
PEG Ratio19.61
Price to Book (P/B)N/A
Price to Sales (P/S)2.44
Price to Cash Flow (P/CF)17.60
P/FCF Ratio16.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$48.94Price Target Upside26.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Andlauer Healthcare Group Business Overview & Revenue Model
Company DescriptionAndlauer Healthcare Group (AND) is a leading Canadian company specializing in transportation and logistics solutions for the healthcare sector. The company operates through various business segments, including specialized transportation, logistics, and distribution services primarily for pharmaceuticals, healthcare products, and medical devices. AND ensures the safe and efficient delivery of sensitive healthcare goods by leveraging its national network, state-of-the-art technology, and industry expertise.
How the Company Makes MoneyAndlauer Healthcare Group makes money by providing comprehensive transportation and logistics services tailored to the healthcare industry. The company's revenue model is primarily based on service fees charged for its specialized transportation services, which include temperature-controlled transportation, dedicated delivery, and last-mile solutions. Additionally, AND generates income through its logistics and distribution services, where it offers warehousing, inventory management, and order fulfillment for healthcare products. Key revenue streams include long-term contracts with pharmaceutical manufacturers, healthcare providers, and distributors. Significant partnerships with major healthcare companies and compliance with stringent healthcare regulations also contribute to its earnings, as these factors help ensure a stable and growing client base.
Andlauer Healthcare Group Financial Statement Overview
Summary
Andlauer Healthcare Group shows strong financial health with efficient operations and a solid cash flow position. The income statement and cash flow metrics are commendable, though the balance sheet suggests moderate leverage which should be monitored.Income Statement
The company displays strong profitability with a consistently positive gross profit margin. The net profit margin shows moderate stability, but there was a slight decline in revenue growth rate recently, indicating potential challenges in sustaining top-line growth. EBIT and EBITDA margins remain healthy, suggesting efficient operational management.78
Positive
Balance Sheet
The balance sheet reveals a solid equity base with a moderate debt-to-equity ratio, indicating manageable leverage. Return on Equity (ROE) is positive, demonstrating effective use of equity to generate profits. However, the equity ratio reflects a moderate reliance on debt financing, which could pose risks if market conditions change.70
Positive
Cash Flow
The company exhibits robust cash flow management with a healthy operating cash flow to net income ratio, and significant free cash flow generation. Free cash flow to net income ratio is strong, but the growth rate of free cash flow has seen some variation, suggesting potential fluctuations in cash availability for reinvestment and debt servicing.82
Very Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 650.48M | 647.95M | 648.42M | 440.12M | 314.34M | Gross Profit |
| 147.20M | 147.48M | 158.85M | 110.75M | 79.55M | EBIT |
| 93.96M | 96.05M | 110.34M | 73.70M | 50.94M | EBITDA |
| 166.72M | 166.96M | 175.07M | 154.91M | 79.20M | Net Income Common Stockholders |
| 64.47M | 66.14M | 76.28M | 89.95M | 37.71M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 40.48M | 59.74M | 65.86M | 24.99M | 30.15M | Total Assets |
| 696.92M | 682.43M | 712.46M | 644.17M | 252.80M | Total Debt |
| 181.21M | 127.90M | 163.29M | 187.25M | 129.61M | Net Debt |
| 140.73M | 68.16M | 97.43M | 162.26M | 99.47M | Total Liabilities |
| 265.78M | 212.86M | 271.47M | 292.05M | 158.47M | Stockholders Equity |
| 431.13M | 469.57M | 440.99M | 352.12M | 94.33M |
| Cash Flow | Free Cash Flow | |||
| 104.02M | 78.83M | 109.17M | 74.42M | 45.56M | Operating Cash Flow |
| 124.40M | 104.42M | 137.13M | 84.09M | 51.00M | Investing Cash Flow |
| -18.86M | -23.85M | -45.56M | -183.38M | -20.37M | Financing Cash Flow |
| -126.24M | -86.18M | -51.59M | 93.89M | -19.20M |
Andlauer Healthcare Group Technical Analysis
Negative
38.56
Price Trends
44.23
Negative
43.22
Negative
41.04
Negative
Market Momentum
-1.66
Positive
25.29
Positive
21.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AND, the sentiment is Negative. The current price of 38.56 is below the 20-day moving average (MA) of 42.95, below the 50-day MA of 44.23, and below the 200-day MA of 41.04, indicating a bearish trend. The MACD of -1.66 indicates Positive momentum. The RSI at 25.29 is Positive, neither overbought nor oversold. The STOCH value of 21.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AND.
Andlauer Healthcare Group Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $386.27M | 15.93 | 25.19% | 2.13% | 0.54% | 276.35% | |
73 Outperform | C$63.88M | 12.64 | 19.57% | ― | 38.28% | ― | |
65 Neutral | $1.56B | 25.15 | 14.34% | 1.12% | 0.39% | 1.28% | |
59 Neutral | $543.45M | ― | -3.84% | ― | 3.87% | -378.27% | |
54 Neutral | C$3.71B | ― | 3.60% | ― | 11.61% | 92.72% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% |
* Healthcare Sector Average
Performance Comparison
TSE:AND
Andlauer Healthcare Group
38.56
-4.24
-9.91%
TSE:DR
Medical Facilities
17.31
8.43
94.87%
TSE:BHC
Bausch Health Companies
10.09
-2.31
-18.63%
TSE:GUD
Knight Therapeutics
6.00
0.69
12.99%
TSE:COV
Covalon Technologies
2.39
1.06
79.70%
Andlauer Healthcare Group Earnings Call Summary
Earnings Call Date: Feb 26, 2025 | % Change Since: -14.52% | Next Earnings Date: Apr 30, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong growth in Canadian operations and improved EBITDA margins, although challenges in the U.S. transportation segment and a decline in packaging revenue persisted. The company remains financially strong and committed to shareholder value initiatives, signaling a cautiously optimistic outlook.Highlights
Strong Canadian Transportation Growth
Canadian ground transportation revenue excluding fuel increased by 8.5%, dedicated and last mile was up 10.2%, and air freight forwarding grew by 5.1% compared to Q3 last year.
Improved EBITDA Margin
Consolidated EBITDA margin reached 25.9% for the quarter, up from 24.9% in Q3 last year, marking the strongest quarterly margin in 2024.
Healthcare Logistics Revenue Growth
Healthcare Logistics segment revenue totaled $44.1 million, an increase of 4.7% compared to Q3 last year, with logistics and distribution revenue increasing by 6.7%.
Strong Financial Position
The company maintained a very conservative net leverage ratio of 0.74x with cash and cash equivalents of $36 million and working capital of $47 million at quarter end.
Continued Shareholder Value Initiatives
The company raised its quarterly dividend to $0.11 per share and continued share buyback activities.
Lowlights
U.S. Transportation Challenges
Continued challenging operating conditions in the U.S. truckload business led to a $1.5 million lower EBITDA in the quarter compared to Q3 last year.
Decline in Packaging Revenue
Packaging revenue declined by 16.7% due to lower volumes.
Lower Contributions from U.S.-based Businesses
Lower contributions from Boyle Transportation and Skelton USA affected overall performance.
Company Guidance
During the Andlauer Healthcare Group's Q3 2024 earnings call, the company provided detailed guidance on its financial performance and strategic focus. The Canadian Grand transportation revenue, excluding fuel, experienced an increase of approximately 8.5% compared to the previous year, while dedicated and last-mile delivery grew by 10.2%, and air freight forwarding rose by 5.1%. The Logistics and Distribution segment saw a 6.8% year-over-year increase in revenue. The consolidated EBITDA margin improved to 25.9%, up from 24.9% in Q3 2023. However, the U.S.-based truckload business faced challenges, with EBITDA attributable to Boyle Transportation and Skelton USA being $1.5 million lower compared to the previous year. Despite these challenges, the company remains focused on improving its specialized U.S. truckload operations and is optimistic about growth opportunities in the Canadian healthcare sector, with plans for organic growth and potential acquisitions. The balance sheet remains strong, with a net leverage ratio of 0.74x and cash and cash equivalents of $36 million.Andlauer Healthcare Group Corporate Events
M&A TransactionsBusiness Operations and Strategy
Andlauer Healthcare Group Forms Joint Venture with NowPac
Positive
Mar 3, 2025
Andlauer Healthcare Group has announced a joint venture between its packaging subsidiary, Nova Pack, and NowPac, a Toronto-based company specializing in contract packaging services for the healthcare sector. This collaboration aims to leverage technology, automation, and AHG’s extensive healthcare supply chain network to offer enhanced contract packaging solutions. The joint venture, equally owned by AHG’s Accuristix and NowPac’s owners, is expected to boost AHG’s cash flow and earnings per share immediately. By combining NowPac’s expertise in packaging with AHG’s logistics capabilities, the partnership is set to enhance efficiency and scalability in healthcare supply chain solutions, providing significant growth opportunities and value for customers.
Stock BuybackBusiness Operations and StrategyFinancial Disclosures
Andlauer Healthcare Group Reports Stable 2024 Financial Results Amid Market Challenges
Neutral
Feb 26, 2025
Andlauer Healthcare Group reported its financial results for Q4 2024 and the full fiscal year, showing slight declines in revenue and operating income compared to the previous year. Despite facing challenges in its US-based truckload businesses, the company experienced growth in its Canadian transportation network and packaging solutions. The company’s low debt levels and strong cash generation provide financial flexibility for future growth opportunities, including share buybacks and capital allocation to enhance value for customers and shareholders.
Executive/Board Changes
Andlauer Healthcare Group Announces Leadership Transition with Retirement of Bob Brogan
Neutral
Feb 4, 2025
Andlauer Healthcare Group announced the retirement of Bob Brogan, the President of Specialty Solutions, effective January 31, 2025. His responsibilities will be taken over by Sandro Caccaro, President of Transportation – Canada, positioning the company for continued success. Brogan’s contributions have been significant since he joined the company in 2001, particularly in expanding AHG’s specialized transportation business.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.